REPLIGEN CORP (RGEN)

↓ Download CSV

CIK 0000730272 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, REPLIGEN CORP reported revenue of $738.26M, up 16.4% from the prior year. The company was profitable, with a net margin of 6.6%. It held $2.95B in total assets against $843.57M in total liabilities.

Key ratios (FY2025)

7.5%
Operating margin
6.6%
Net margin
2.3%
Return on equity
+16.4%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$738.26M$634.44M$632.36M$801.54M$670.53M$366.26M$270.25M$194.03M$141.24M$104.54M
Cost of Revenue$352.01M$359.79M$353.92M$345.83M$279.28M$156.63M$119.10M$86.53M$67.05M$47.12M
Operating Income$55.17M-$35.11M$47.70M$224.67M$167.25M$69.82M$36.08M$25.99M$14.01M$15.97M
Net Income$48.89M-$25.51M$35.60M$185.96M$128.29M$59.93M$21.41M$16.62M$28.35M$11.68M
EPS (Diluted)$0.86$-0.46$0.63$3.24$2.24$1.11$0.44$0.37$0.72$0.34
Total Assets$2.95B$2.83B$2.83B$2.53B$2.36B$1.90B$1.40B$774.62M$743.52M$288.91M
Total Liabilities$843.57M$856.95M$866.34M$620.90M$608.29M$373.74M$340.35M$159.05M$151.97M
Shareholders' Equity$2.11B$1.97B$1.96B$1.91B$1.75B$1.53B$1.06B$615.57M$591.55M$168.76M
Cash & Equivalents$566.02M$757.36M$751.32M$523.46M$603.81M$717.29M$528.39M$193.82M$173.76M$122.23M
Operating Cash Flow$117.42M$175.39M$113.92M$172.08M$119.02M$62.62M$67.22M$32.77M$17.45M$7.52M
Capital Expenditures$23.52M$25.68M$36.22M$84.83M$67.09M$22.45M$18.50M$10.63M$5.45M$4.33M
Shares Outstanding56.6K55.9K56.4K57.5K57.3K53.9K49.21M45.47M39.15M34.1K